Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    AGBA

    MCap

    USD77m

    Last close

    USD1.03

    ▲ 0.63 (157.50%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    Sareum Holdings

    MCap

    GBP28m

    Last close

    GBP0.27

    ▲ 6.25 (30.49%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Aditxt business update with Amro Albanna, co-founder and CEO

Aditxt business update with Amro Albanna, co-founder and CEO

Aditxt — 2 videos in collection

More on this equity

Aditxt is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. The company’s immune mapping technologies are designed to provide a personalised immune profile. Its immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies.

In this webinar, Aditxt’s CEO, Amro Albanna, is joined by Jason Kolbert, a research analyst at Dawson James. Jason asks Amro about overall business updates and milestones and the company’s acquisition strategy.

< Previous
Next >

You may also be interested in these:

Healthcare

Aditxt: Edison Open House Healthcare 2022

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free